Literature DB >> 21715579

N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.

Mayumi Tachibana1, Yimin Wu, Hideyuki Iriko, Olga Muratova, Nicholas J MacDonald, Jetsumon Sattabongkot, Satoru Takeo, Hitoshi Otsuki, Motomi Torii, Takafumi Tsuboi.   

Abstract

The aim of a malaria transmission-blocking vaccine is to block the development of malaria parasites in the mosquito and thus prevent subsequent infection of the human host. Previous studies have demonstrated that the gametocyte/gamete surface protein Pfs230 can induce transmission-blocking immunity and have evaluated Escherichia coli-produced Pfs230 as a transmission-blocking vaccine candidate. In this study, we used the wheat germ cell-free expression system to produce N-terminal fragments of Pfs230 and evaluated the transmission-blocking activity of antisera raised against the recombinant Pfs230 protein. The rabbit antisera reacted to the surface of cultured gametocytes and gametes of the Plasmodium falciparum NF54 line, recognized the 360-kDa form of parasite-produced Pfs230 by Western blot assay, and reduced the infectivity of NF54 parasites to Anopheles stefensi mosquitoes in the presence of complement in a standard membrane feeding assay. Thus, our data demonstrate that the N-terminal pro domain of Pfs230 is sufficient to induce complement-dependent transmission-blocking activity against P. falciparum.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715579      PMCID: PMC3147338          DOI: 10.1128/CVI.05104-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  43 in total

1.  Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum.

Authors:  Dietlind L Gerloff; Alison Creasey; Siarhei Maslau; Richard Carter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-09       Impact factor: 11.205

2.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Authors:  Elissa M Malkin; Anna P Durbin; David J Diemert; Jetsumon Sattabongkot; Yimin Wu; Kazutoyo Miura; Carole A Long; Lynn Lambert; Aaron P Miles; Jin Wang; Anthony Stowers; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

3.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

4.  Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.

Authors:  D C Kaslow; I C Bathurst; T Lensen; T Ponnudurai; P J Barr; D B Keister
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

Review 5.  Malaria: progress, perils, and prospects for eradication.

Authors:  Brian M Greenwood; David A Fidock; Dennis E Kyle; Stefan H I Kappe; Pedro L Alonso; Frank H Collins; Patrick E Duffy
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility.

Authors:  Melissa R van Dijk; Ben C L van Schaijk; Shahid M Khan; Maaike W van Dooren; Jai Ramesar; Szymon Kaczanowski; Geert-Jan van Gemert; Hans Kroeze; Hendrik G Stunnenberg; Wijnand M Eling; Robert W Sauerwein; Andrew P Waters; Chris J Janse
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

Review 7.  Do we still need a malaria vaccine?

Authors:  B Greenwood; G Targett
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

8.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

9.  Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia.

Authors:  J Teun Bousema; Will Roeffen; Mike van der Kolk; Sake J de Vlas; Marga van de Vegte-Bolmer; Michael J Bangs; Karina Teelen; Liliana Kurniawan; Jason D Maguire; J Kevin Baird; Robert W Sauerwein
Journal:  Am J Trop Med Hyg       Date:  2006-03       Impact factor: 2.345

10.  Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Authors:  Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  43 in total

1.  Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

Authors:  Nicholas J MacDonald; Vu Nguyen; Richard Shimp; Karine Reiter; Raul Herrera; Martin Burkhardt; Olga Muratova; Krishan Kumar; Joan Aebig; Kelly Rausch; Lynn Lambert; Nikiah Dawson; Jetsumon Sattabongkot; Xavier Ambroggio; Patrick E Duffy; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 2.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Authors:  Rajesh Kumar; Paresh C Ray; Dibyadyuti Datta; Geetha P Bansal; Evelina Angov; Nirbhay Kumar
Journal:  Vaccine       Date:  2015-08-20       Impact factor: 3.641

Review 4.  The s48/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle.

Authors:  Silvia A Arredondo; Stefan H I Kappe
Journal:  Int J Parasitol       Date:  2016-11-27       Impact factor: 3.981

5.  Targeting molecular interactions essential for Plasmodium sexual reproduction.

Authors:  Joel Vega-Rodriguez; Davinia Perez-Barreto; Antonio Ruiz-Reyes; Marcelo Jacobs-Lorena
Journal:  Cell Microbiol       Date:  2015-05-29       Impact factor: 3.715

6.  A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.

Authors:  Christine E Farrance; Amy Rhee; R Mark Jones; Konstantin Musiychuk; Moneim Shamloul; Satish Sharma; Vadim Mett; Jessica A Chichester; Stephen J Streatfield; Will Roeffen; Marga van de Vegte-Bolmer; Robert W Sauerwein; Takafumi Tsuboi; Olga V Muratova; Yimin Wu; Vidadi Yusibov
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

7.  ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.

Authors:  Kazutoyo Miura; Bingbing Deng; Yimin Wu; Luwen Zhou; Thao P Pham; Ababacar Diouf; Chia-Kuei Wu; Shwu-Maan Lee; Jordan L Plieskatt; Merribeth J Morin; Carole A Long
Journal:  Vaccine       Date:  2019-03-05       Impact factor: 3.641

8.  Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.

Authors:  Kazutoyo Miura; Eizo Takashima; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Daria Nikolaeva; Mahamadou Diakite; Rick M Fairhurst; Michael P Fay; Carole A Long; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.

Authors:  Rajesh Kumar; Evelina Angov; Nirbhay Kumar
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

10.  Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential.

Authors:  Fei Liu; Li Li; Wenqi Zheng; Yiwen He; Yaru Wang; Xiaotong Zhu; Takafumi Tsuboi; Liwang Cui; Meilian Wang; Yaming Cao
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.